Company / Working Capital per Share
Neurocrine Biosciences Working Capital per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital per Share
$17.90
FY2025
5-year range
$7.78 / $17.90
FY2021-FY2025
Trend
+45.2%
vs FY2024
Sector context
#22 of 212
Health Care
What the data says
Among 212 Health Care companies, Neurocrine Biosciences is in the top 10% for working capital per share. Working Capital per Share has increased for 4 consecutive years, from $7.78 in FY2021 to $17.90 in FY2025.
Based on SEC 10-K filings.
17.90 in FY2025 with a 5-year CAGR of +14.8%. Top quartile in the Health Care sector.
Improved from $9.87 to $17.90 over the past 2 years.
Health Care sector context is included.
Working Capital per Share over time
Growth rates
- 3-Year CAGR
- +22.9%
- 5-Year CAGR
- +14.8%
- 10-Year CAGR
- -
Sector benchmark
-84.8% below sector average
Key checks
Key Insights
- Neurocrine Biosciences's working capital per share has grown for 4 consecutive years.
- In FY2025, working capital per share increased 45.2% year-over-year.
- Ranks #22 out of 212 companies in the Health Care sector.
- Lowest working capital per share in the period was in FY2019.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working Capital per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $17.90 | +45.2% |
| FY2024 | $12.33 | +25.0% |
| FY2023 | $9.87 | +2.3% |
| FY2022 | $9.65 | +24.1% |
| FY2021 | $7.78 | -13.5% |
| FY2020 | $8.99 | +207.2% |
| FY2019 | $2.93 | -60.0% |
| FY2018 | $7.32 | +27.0% |
| FY2017 | $5.76 | +77.5% |
| FY2016 | $3.25 | -30.7% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026